BriaCell Therapeutics Drops 4% Following Metastatic Breast Cancer Trial Results

(RTTNews) - BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a clinical response in a metastatic breast cancer patient treated with its personalized off-the-shelf immunotherapy, Bria-OTS. Despite the resolution of a lung metastasis in one patient, the broader implications of the treatment have overshadowed the news.

BCTX is currently trading at $4.78, down 4.71 percent or $0.23 on the Nasdaq. The stock has experienced notable fluctuations today, with a high of $7.87 and a low of $5.18, as investors reacted cautiously to the announcement. The total volume for the day is 13.3 million shares, significantly higher than the average volume of 1.31 million.

Bria-OTS is still being tested in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer, an experimental therapy that follows BriaCell's lead candidate, Bria-IMT, which is currently undergoing a pivotal Phase 3 study for metastatic breast cancer.